AE	Adverse event
AI	Aromatase inhibitor
AKT	Ak strain transforming
ALT	Alanine transaminase
AST	Aspartate aminotransferase
BC	Breast cancer
BP	Blueprint
BRCA	Breast cancer gene
CBR	Clinical benefit rate
CDK4/6i	Cyclin-dependent kinase 4/6 inhibitor
CPS	Combined positive score
CT	Chemotherapy
CTLA-4	Cytotoxic T-lymphocyte-associated protein 4
DCR	Disease control rate
ddAC	Dose-dense doxorubicin plus cyclophosphamide
DDR	DNA damage response
DOR	Duration of response
EBC	Early breast cancer
EC	Epirubicin plus cyclophosphamide
EFS	Event-free survival
ER	Estrogen receptor
ET	Endocrine therapy
FOXP3	Forkhead box P3
HDAC	Histone Deacetylase
HER2	Human epidermal growth factor receptor 2
ICI	Immune checkpoint inhibitor
IDFS	Invasive disease-free survival
ILD	Interstitial lung disease
KN-756	KEYNOTE-756
LAG3	Lymphocyte activation gene 3
LumB	Luminal B
MBC	Metastatic breast cancer
mDOR	Median duration of response
MHC	Major histocompatibility complex
mo	months
MP	Mammaprint
mPFS	Median progression free survival
mTNBC	Metastatic triple-negative breast cancer
mut/MB	Mutations per Megabase
NA	Not applicable
NACT	Neoadjuvant chemotherapy
NR	Not reported
ORR	Objective response rate
OS	Overall survival
PAM50	Prediction analysis of microarray 50
PARPi	Poly (ADP-ribose) polymerase inhibitor
pCR	Pathological complete response
PD-1	Programmed cell death protein 1
PD-L1	Programmed cell death-ligand 1
PR	Partial response
RCB	Residual cancer burden
RT	Radiation therapy
SBRT	Stereotactic body radiation therapy
SD	Stable disease
STING	Stimulator of interferon genes
TAM	Tumor-associated macrophages
TIL	Tumor-infiltrating lymphocytes
TMB	Tumor mutation burden
TME	Tumor microenvironment
TNBC	Triple-negative breast cancer
TRAE	Treatment-related adverse events
Treg	Regulatory T cells